IRVINE, Calif.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc., (Nasdaq:SPPI) today announced that the Therapeutic Product Directorate of Health Canada has approved the trials to be conducted in Canada by issuing a No Objection Letter to Spectrum’s Clinical Trial Application for EOquin®, the Company’s drug candidate in Phase 3 clinical trials for non-invasive bladder cancer. Phase 3 protocols are open and currently recruiting patients in the United States. This action authorizes the initiation of clinical trials in Canada, where preparations have been underway for several months.
